Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
Garcia-Manero G., Daver N., Xu J., Chao M., Chung T., Tan A., Wang Y., Wei A., Vyas P., Sallman D.